Prognostic Panel Helps Identify Lupus Patients at Risk for Kidney, Brain, or Cardiovascular Involvement
|
By LabMedica International staff writers Posted on 24 Jun 2014 |
|
In response to physician requests to help fulfill an unmet need, the new prognostic test helps assess potential risk of various Lupus related complications.
Lupus patients can suffer from disease flares that can become destructive to any organ or tissue in the body. Exagen Diagnostics, Inc. (Albuquerque, NM, USA), a leading diagnostics development company focused in rheumatology, has launched the addition of "Avise SLE Prognostic" to its testing services. Designed to supplement the "Avise SLE+ Connective Tissue" diagnostic, the Avise SLE Prognostic panel helps physicians assess potential risk for lupus nephritis, neuropsychiatric SLE (Systemic lupus erythematosus), thrombosis, and cardiovascular events.
The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space. The panel includes the following markers: anti-C1q – prognostic factor for lupus nephritis; anti-Ribosomal P – prognostic factor for neuropsychiatric SLE; and anti-phosphatidylserine/prothrombin (PS/PT) (IgM, IgG) – prognostic factor for thrombosis in SLE. Also, prognostic factors for thrombosis and cardiovascular events – anti-cardiolipin (IgM, IgG, IgA) and anti-β2-Glycoprotein 1 (IgM, IgG, IgA) – are indirectly included in the Avise SLE+ Connective Tissue 2.0 diagnostic or as an add-on to Avise SLE 2.0.
Complimenting Avise SLE 2.0 or Avise SLE+ Connective Tissue 2.0, Avise SLE Prognostic uses the same blood draw specimen as for the diagnostic and offers pre-provided kits, pre-paid Fedex, limited patient out-of-pocket cost, and high quality data based results within 7 days.
"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients," said Ron Rocca, Exagen President and CEO.
Related Links:
Exagen Diagnostics
Avise Tests
Lupus patients can suffer from disease flares that can become destructive to any organ or tissue in the body. Exagen Diagnostics, Inc. (Albuquerque, NM, USA), a leading diagnostics development company focused in rheumatology, has launched the addition of "Avise SLE Prognostic" to its testing services. Designed to supplement the "Avise SLE+ Connective Tissue" diagnostic, the Avise SLE Prognostic panel helps physicians assess potential risk for lupus nephritis, neuropsychiatric SLE (Systemic lupus erythematosus), thrombosis, and cardiovascular events.
The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space. The panel includes the following markers: anti-C1q – prognostic factor for lupus nephritis; anti-Ribosomal P – prognostic factor for neuropsychiatric SLE; and anti-phosphatidylserine/prothrombin (PS/PT) (IgM, IgG) – prognostic factor for thrombosis in SLE. Also, prognostic factors for thrombosis and cardiovascular events – anti-cardiolipin (IgM, IgG, IgA) and anti-β2-Glycoprotein 1 (IgM, IgG, IgA) – are indirectly included in the Avise SLE+ Connective Tissue 2.0 diagnostic or as an add-on to Avise SLE 2.0.
Complimenting Avise SLE 2.0 or Avise SLE+ Connective Tissue 2.0, Avise SLE Prognostic uses the same blood draw specimen as for the diagnostic and offers pre-provided kits, pre-paid Fedex, limited patient out-of-pocket cost, and high quality data based results within 7 days.
"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients," said Ron Rocca, Exagen President and CEO.
Related Links:
Exagen Diagnostics
Avise Tests
Gold Member
Troponin T QC
Troponin T Quality Control
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
TRAb Immunoassay
Chorus TRAb
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
